Pacific Biosciences is trading 6.14% down now at $1.07, with no fresh company-specific announcement identified for August 12, 2026.

  • The Nasdaq Composite is up 0.50% and the S&P 500 is up 0.17%, despite the decline.
  • The latest clear catalyst remains the August 5 earnings update: revenue missed expectations, 2026 guidance was reduced, and cash-flow breakeven was pushed to 2028.
  • That update does not directly explain today’s move.